Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 22.80% is 40% above its 5-year average of 16.26%, near the high end of its 5-year range (-4.15%–25.91%).
0.41% above its 12-month average of 22.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 24.40%.
EBITDA MARGIN
22.80%
EBITDA MARGIN AVG TTM
22.71%
EBITDA MARGIN AVG 3Y
21.19%
EBITDA MARGIN AVG 5Y
16.26%
EBITDA MARGIN AVG 10Y
16.87%
EBITDA MARGIN AVG 15Y
10.91%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.41%
CURRENT VS 3Y AVG
+7.59%
CURRENT VS 5Y AVG
+40.19%
CURRENT VS 10Y AVG
+35.12%
CURRENT VS 15Y AVG
+109.06%
CURRENT VS 20Y AVG
N/A
Market Cap
$469.71M
EBITDA Margin
-41.77%
TTM Avg
-67.13%
3Y Avg
-207.81%
5Y Avg
-270.93%
Market Cap
$469.66M
EBITDA Margin
-26.24%
TTM Avg
-39.04%
3Y Avg
-67.96%
5Y Avg
-45.86%
Market Cap
$468.55M
EBITDA Margin
-3.52%
TTM Avg
-5.19%
3Y Avg
-11.78%
5Y Avg
-23.46%
Market Cap
$471.56M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$474.32M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$465.75M
EBITDA Margin
-47.32%
TTM Avg
-54.85%
3Y Avg
-73.89%
5Y Avg
-85.45%
Market Cap
$484.69M
EBITDA Margin
-9.71%
TTM Avg
-10.19%
3Y Avg
-20.82%
5Y Avg
-63.11%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kamada Ltd. (KMDA) | $469.86M | 22.80% | 22.71% | 21.19% | 16.26% |
| Arvinas, Inc. (ARVN)vs › | $469.71M | -41.77% | -67.13% | -207.81% | -270.93% |
| Alpha Teknova, Inc. (TKNO)vs › | $469.66M | -26.24% | -39.04% | -67.96% | -45.86% |
| Cerus Corporation (CERS)vs › | $468.55M | -3.52% | -5.19% | -11.78% | -23.46% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.56M | -31.76% | -31.76% | -31.76% | -31.76% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $474.32M | N/A | N/A | N/A | N/A |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | -47.32% | -54.85% | -73.89% | -85.45% |
| Evolus, Inc. (EOLS)vs › | $484.69M | -9.71% | -10.19% | -20.82% | -63.11% |
| NRC Health (NRC)vs › | $454.45M | 21.99% | 25.40% | 28.98% | 31.97% |
| Puma Biotechnology, Inc. (PBYI)vs › | $485.07M | 21.12% | 19.78% | 18.26% | 11.49% |
Gross Margin
40.8%
EBITDA Margin
22.8%
Operating Margin
14.5%
Net Margin
11.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 24.40% |
| 2026-03-31 | 23.88% |
| 2025-12-31 | 16.46% |
| 2025-09-30 | 24.62% |
| 2025-06-30 | 24.17% |
| 2025-03-31 | 25.91% |
| 2024-12-31 | 23.53% |
| 2024-09-30 | 20.45% |
| 2024-06-30 | 20.88% |
| 2024-03-31 | 19.28% |
| 2023-12-31 | 16.43% |
| 2023-09-30 | 19.90% |
| 2023-06-30 | 15.58% |
| 2023-03-31 | 11.11% |
| 2022-12-31 | 15.47% |
| 2022-09-30 | 17.43% |
| 2022-06-30 | 3.25% |
| 2022-03-31 | 11.65% |
| 2021-12-31 | -4.15% |
| 2021-09-30 | 1.89% |
| 2021-06-30 | 9.37% |
| 2021-03-31 | 14.10% |
| 2020-12-31 | 12.41% |
| 2020-09-30 | 25.52% |
| 2020-06-30 | 15.60% |
| 2020-03-31 | 18.15% |
| 2019-12-31 | 20.66% |
| 2019-09-30 | 20.64% |
| 2019-06-30 | 21.32% |
| 2019-03-31 | 23.64% |
| 2018-12-31 | 33.75% |
| 2018-09-30 | -11.02% |
| 2018-06-30 | 18.19% |
| 2018-03-31 | 12.51% |
| 2017-12-31 | 20.50% |
| 2017-09-30 | 2.57% |
| 2017-06-30 | 18.08% |
| 2017-03-31 | -24.27% |
| 2016-12-31 | -4.22% |
| 2016-09-30 | -0.50% |
| 2016-06-30 | 1.51% |
| 2016-03-31 | -7.75% |
| 2015-12-31 | 6.12% |
| 2015-09-30 | -19.57% |
| 2015-06-30 | -8.60% |
| 2015-03-31 | -55.76% |
| 2014-12-31 | 11.40% |
| 2014-09-30 | -10.33% |
| 2014-06-30 | -45.82% |
| 2014-03-31 | -15.50% |
| 2013-12-31 | 12.82% |
| 2013-09-30 | 9.78% |
| 2013-06-30 | 14.52% |
| 2013-03-31 | -3.82% |
| 2012-12-31 | 20.04% |
| 2012-09-30 | 12.13% |
| 2012-06-30 | -2.09% |
